| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
The aim of study was to determine whether peripheral blood-based parameter (PBBP) is significant for predictive efficacy in HER2-positive ABC treated with anti-HER2 antibodies. The 51 patients' data from clinical trials was included in this retrospective-prospective study. In consideration of PBBP, we evaluated PBBP including absolute lymphocyte count (ALC). The PFS of patients with ALC-High was significantly better than those of ALC-low. Furthermore, improved PFS was obtained in patients with ALC greater than 1500 cells/μL compared with less than 1000 cells/uL. Pre-treatment ALC-High was significantly correlated with favorable PFS of patients in HER2-positve ABC. Prolonged PFS might be obtained mediating through host systemic immunity in cancer treatment. These data obtained here suggest that a usefulness of ALC for selecting patients who might have clinical benefit for heavily treated HER2-positve ABC.
|
